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Local Delivery of a Synthetic Antithrombin With a Hydrogel-Coated
Angioplasty Balloon Catheter Inhibits Platelet-Dependent Thrombosis
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RON A . SAHATJIAN, PHD," NEAL A. SCOTT, MD, PHD, FACC
Atlanta, Georgia and Watertown, Massachusetts
Objectives . This study evaluated the e®cacy of local adminis.
S cation of an antithranbin agent with a bydrogd<oated pereuta-
meous transluminal coronary nagioplasty balloon catheter.
Background.
Intravenous infusion of antthrombio compounds
has been shown to inhibit pktekl-dependent thrombosis . How-
ever, hemorrhage is a common side effect asseciated with the
systemic adminlstratimr of antltromble compounds .
Methods . The potent, irreversible thromble inhibitor Ir-Phc-L-
Pro-L-Arginyl chloromo hyl ketaue (PPACK) was used to Inhibit
thrombus formation In chronic porcine arlerlovenous shoos,
Platelet deposition was quantitated with gamma carvers Imaging
of 11r tn-labeled platelets.
Results. Intravenous admfa6irstlon of PPACK it swine, in
doses
sufficient
to maximally inhibit thrombus formation, was
associated with prolongation d bleeding parameters. The Initial.
lion of thrombosis associated with intravenous PPACK was doe
related. The amount of intravenous PPACK necessary for maxi-
Unstable angina is a common indication for percutaneous
transluminal coronary angioplasty (I)
. Angioscopic and au-
topsy studies in patients with unstable angina have impli-
cated intracoronary thrombosis as the major etiologic factor
(2-4). The thrombi associated with unstable angina appear to
be composed primarily of platelets (2) . as opposed to the
fibrin-rich thrombi that are found in venous vessels (5) .
Although heparin effectively inhibits fibrin-rich thrombus
formation, platelet-dependent thrombosis is largely resistant
to conventional therapy with heparin (6,7) . Thrombin, gen-
erated on the platelet surface, initiates potent positive feed-
back mechanisms for local activation of the coagulation
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and inhibition of thrombus formation for a period of 45 rain was
16
.9 mg
. in contrast, kcal delivery of PPACK with a bydrogel-
coated angioplasty William deployed at the site of the thrombus
Inhibited platelet deposition for at east 45 aft alter the balloon
was rarovai- Using 41-labeled PPACK, the calculated anosat of
TACK delivered was 33.5 pg- There was so change in bleeding
time or activated partial lInamboplasiin time when swine received
an Intravenous bobs greater than The total mount of PPACK
adsorbed onto the balloon (70 pg)-
Concludons. These rune is suggest teat In this model, a hydrogd-
coated coronary angioptasty balloon catheter ma
be and to
deliver enough antniramtria agent to Inhibit pdateieh-depends nt
thrombosis far at feast 45 a1In at doss
thatme several orders of
magnltnde its thna than required for syssede adddslntion . to
addition, local delivery can provide effective inhibition of throw
has formation without alteration et bleeding parameters.
(I
Am Cog Cat" 1994:23:1578-83)
cascade, forming large amounts of thrombin (8,9) . Platelet
activation by thrombin has been implicated as an impoitant
component in the arterial thrombotic process (I0)- Although
intravenous administration of antagonists of thrombin effec-
tively inhibits platelet-dependent thrombosis, prolongation
of bleeding parameters is a common side effect (6.11,12) .
Preliminary studies have suggested that local administration
of a synthetic thrombin inhibitor can inhibit thrombosis at
doses far below the threshold for prolongation of systemic
bleeding parameters (13). This study was therefore per-
formed to test the feasibility of inhibiting platelet-dependent
thrombosis with local delivery of an antithrombin compound
via a coronary angioplasty balloon catheter .
Methods
Surgical procedures. Normal domestic swine (weight 28
to 35 kg) were used in these studies and were observed to be
disease free for at least I week before use . All procedures
were approved by the Emory University Institutional Ani-
mal Care and Use Committee in accordance with federal
guidelines (14) . All animals had a chronic a :reriovenous
shunt surgically implanted between the common carotid
artery and external jugular vein . Ketamine hydrochloride
(10 mg(kg body weight, intramuscularly) was given as a
0735 .t097194157'
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Dacron Graft
Figure 1. A
chronic arteriovenous shunt in a pig. The cannulas are
inserted into the common carotid artery and external jugular vein .
Extension tubing containing a segment of Dacron graft has been
incorporated into the shunt.
preanesthetic agent, and the operation was perforated while
the animals were endotracheally intubated and ventilated
under 1% isothane general anesthesia. The permanent shunt
system consisted of two 10-cm lengths of Silastic tubing with
a 3 .0-mm inside diameter (Dow Corning) . Blood flow was
established by connecting the two Silastic shunt segments
with a curved 2-cm length of Teflon tubing (2 .8 mm inside
diameter) . After a 3-day recovery period, the shunt studies
were performed . All shunt studies were performed in con-
scious animals that were sedated with diazepam and ket-
tmtine .
Uncrimped knitted Dacron grafts (Sauvage external ve-
lour, mean porosity 2,000 to 2,200 ml of water/min at
120 mm Hg) were obtained from Bard Inc . All grafts were
2 cm in length with a 4 .0-mm internal diameter . Before
evaluation in the arteriovenous shunt system, the grafts were
rendered impervious to blood leakage by an external wrap-
ping of Pnraflim (American Can Company) and placement
inside a 5-cm length of 5
.3-mm inside diameter "heat-
shrink" Teflon tubing (Small Pouts). Silicone rubber tubing,
10-cm x 4.0-mm inside diameter, was connected to both
ends of the graft segment with Silostic medical adhesive
(type A, Dow Corning) . This procedure produced impervi-
ous grafts rigidly constrained to a linear geometry and with
an inner diameter of precise dimensions (4
.0 mm). The
resulting flow channel was smooth in its transition from the
Silastic to the graft without imperfection due to the coupling
procedure. The avoidance of a hemodynamic "step" at the
graft junctions has been fatnd to be essential to ensure
reproducible and uniform platelet deposition after blood
exposure (15). The 4 .0-mm inside diameter Silastic tubing
segments proximal and distal to the Dacron graft were
subsequently connected to the 3 .0-mm inside diameter Silas-
tic tubing comprising the chronic arterinvenous shunt with
2-cm long tapered Teflon connectors (Shall Parts) (Fig. I) .
Mean blood flow rates through vascular graft segments
incorporated into the arteriovenous shunt system were mea-
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sured continuously by using an ultrasound flowmeter (Tran-
sonics, model 2101) with a transducer probe that fit snugly
around the Silastic tubing comprising the chronic shunt . In
all studies initial blood flow rates were >200 ml/min . Dacron
grafts were initially placed and imaged after the injection of
autologous "hn-labeled platelets (see later) . The Dacron
graft segments were imaged for 2 h and then removed .
Platelet labeling and imaging . Platelet count and hemato-
crit determinations were performed on whole blood col-
lected in disodium ethytenediaminetetraacetic acid at 2
mg/mi using a Baker model 810 whole-blood analyzer .
Autologous porcine blood platelets were labeled with 7 " In-
labeled Bxine, as previously described (15). Briefly, whole
blood (55 ml) was collected directly into plastic syringes
(TA-3, Femval Laboratories) containing 8 ml of acid/eitratel
dextrose anticoagulant compound (National Institutes of
Health
. formula A)
. The blood was centrifuged at 300 x g for
10 min. The supernatant platelet-rich plasma ws transferred
to a plastic tube, and the pH was adjusted to 6 .5 by the
addition of 0.15 mol/liter of citric acid (0 .1 mb'lU ml of
platelet-rich plasma) . The platelets were formed into a pellet
by centrifugation of the platelet-rich plasma at 1,300 x g for
15 min . The supernatant platelet-poor plasma was com-
pletely decanted and discarded. To remove residual plasma
proteins, the tube containing the platelet pellet was carefully
washed by overlaying with 20 ml of Ringer's citrate dextrose
(pH 6 .5) . which was decanted and discarded . The pellet was
then gently rc>uspended in 5
.0 ml of Ringer's citrate dex-
trose and incubated for 30 min with 800 to 1,000 mCi (I Ci =
37 e3Bq) of "'In-labeled using (MediPhysics) . Labeling
efficiencies averaged >85%.
Images of the grafts, including proximal and distal Silastic
segments . were acquired with a General Electric Starcam
scintillation camera (model 4045 89GN2) . Immediately be-
fore imaging the vascular grafts, images were also acquired
of the 4.0-mm inside diameter Silastic tubing filled with
autologous blood and with the same lumen volume as the
graG segment (blood standard) . The activities of the standard
and 2-cm graft segments were measured in the same 3-cm x
6-cm region of interest (10 x 26 pixels), as defined by image
analysis software routines. Images were acquired at 5-min
intervals
. Deposited "Iln-labeled platelet activity, calcu-
Inted by subtracting the blood standard activity from all
dynamic study images, increased monotonically over the
exposure period . The total number of platelets deposited
after 2 h (labeled plus unlabeled cells) was calculated by
dividing the deposited platelet activity (cpm) by the blood
standard platelet activity (cpm/ml) and multiplying by the
circulating platelet count (platelets/mi) (15) .
Hydrogel coating . The hydrogel coating for the balloon
catheters was made from a high molecular weight, medical
grade, soluble polyacrylic acid polymer
(16) . The polymer
was covalently bound to the polyethylene balloon by a
chemical reaction that utilized a cross-linker
. The thickness
was controlled to achieve a total thickness of 5 to 10 µm . The
coating, when placed in contact with water, swelled to
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approximately two to five times its initial thickness . The
polymer coating was buffered to maintain a neutral charge at
pH 7.0. Dip coating was performed by inflating the balloon to
its nominal pressure (6 arm), immersing it in the PPACK
solution for -10 s and air-drying the balloon for -1 min .
This procedure was repeated for a total of three times for
each balloon
. The balloon was then deflated and placed on a
dry surface until use. All balloons were used on the same day
that they were coated, Each balloon used in this study had
an inflated diameter of 4 .0 mm and was 2.0 cm long. The
balloons were inflated with a Boston Scientific inflation
device filled with 0.9% NaCl .
Local delivery protocol. Extension tubing containing the
Dacron graft was connected to the animal for 15 min .
Previous studies have shown that this period of time is
sufficient for the formation of a nonocclusive mural throm-
bus on the Dacron. The tubing was then disconnected from
the animal and gently flushed with 0 .9% NBC] . The balloon
was placed at the site of the Dacron graft and inflated for
15 min . The balloon was then deflated and gently withdrawn .
The extension tubing was gently flushed with 0 .9% NaCl and
reconnected to the animal . Gamma camera imaging was per-
formed throughout the study .
Estimation of PPACK deployed with the coated balloon . In
an attempt to estimate the maximal amount of antithrombin
delivered to the thrombus during the balloon inflation, six
coated balloons were dipped in a solution of 3 H-labeled
PPACK (3
.3 mg of 31-1-labeled PPACK in 1 .0 ml of 0.9%
NaCl) and dried . The balloons were cut off their catheters,
placed in a scintillation vial and counted in a well counter
.
Another six balloons were dipped in a similar solution of
3 H-labeled PPACK and placed at the site of a thrombus on a
Dacron graft that had been exposed to blood flowing in an
arteriovenous shunt for 15 min. The balloon was expanded
for 15 min, deflated and withdrawn in a manner identical to
that described earlier . The balloons were cut from the cathe-
ters, placed in scintillation vials and counted . The maximal
amount of PPACK that could be delivered to the thrombus was
calculated by subtracting the counts per minute of thedeployed
balloons from the undeployed balloons and dividing by the
specific activity (cpnt/pl) of the 3 H-labeled PPACK solution.
Bleeding time measurements. Bleeding time measure-
ments were performed in duplicate an the shaved dorsal
surface of the ear with a commercially available kit (Organon
Tekinca) .
Statistics. Data presented are as mean values t SEM . All
statistical analyses were done using statistical analysis soft-
ware available for an IBM personal computer (SigmaStat) .
Statistical Comparisons for more than two groups were made
using analysis of variance with repeated measures followed
by the Dunnett test .
Results
There were a total of 47 shunt studies performed in 17
animals. Systemic and local administration of PPACK was
1 .5
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i
0.5
0 .0
JACC Vol . 23, No . 7
June 1999:1578-83
1 .
s0 too 120
TIME (min)
F/gare 2 . Effect or intravenous administration of the thrombin
inhibitor PPACK on platelet-dependent thrombus formation. Infu-
sion of PPACK (solid bar) produced a dose-related decrease in
ptatetet-dependent thrombus formation . Slid circles = I pg/tcg per
min of PPACK (n = 611 open tetaagtes = 5 p0Acg per min of PPACK
(n=6) ; solid Utrtgles = 12 .5 pglkg per min of PPACK (n =6) ; open
squares = control (n = 7) .
studied in separate groups of animals . The circulating plate-
let counts averaged 470,000 ± 26
.000 platelets/ml, and the
mean hematocrit was 29.0 t 0.6. Blood flow rates in the
arteriovenous shunt were controlled in the range 80 to
100 mt/mm during the study . Gamma camera images dis-
played uniform distribution of radioactivity over the entire
length of the graft.
Untreated Dacron grafts displayed a ntonotonic deposi-
tion of platelets over a 1-h period . Occlusion of the graft
frequently occurred after I h in the shunt . Intravenous
administration of PPACK produced a dose-dependent inhi-
bition of platelet deposition on the thrombogenic Dacron
graft (Fig . 2). The inhibition was significantly different from
control values at the dose of 5 pglkg per min, and was
maximal at the 12 .5-pg/kg per min dose . After termination of
each infusion of PPACK, there was an increase in platelet
deposition within t5 min. There was no significant change in
bleeding time at the 1 .0- and 5 .0-pg/kg per min doses ;
however, bell, bleeding time and activated partial thrombo-
plastin time increased significantly with the 12 .5-pg/kg per
min dose (Table 1) . These variables returned to normal I h
after the termination of the infusion .
In contrast to the intravenous infusion, local administra-
tion of PPACK with the hydrogel-coated balloon signifi-
cantly inhibited thrombus formation (Fig . 3) . Although the
balloon was deployed :or 15 min, the antithrombotic effect
persisted for at least 45 min after the balloon was removed
and the shunt was reconnected to the animal . When PPACK
was applied to a coronary angioplasty balloon that was not
coated with the hydrogel, there was no difference in platelet
IACC
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deposition when compared with a regular or hydrogel-coated
balloon dipped in vehicle (saline solution).
When smaller doses of PPACK were used there was less
of an inhibitory effect on platelet deposition
. There was no
difference from control values w :len the balloon was dipped
in a
solution of 0.1 mg/ml of PPACK . When a dose of
0 .3 mg/ml was used, there was a trend toward less platelet
deposition . However, the difference was not statistically
significant when compared with control values (data not
shown).
To estimate the amount of PPACK deployed onto the
thrombus with the coated balloon, a solution containing
3 .3 rng(mi of 3H-labeled PPACK was used to coat two groups
of balloons. Both groups of balloons were dipped in the
3H-labeled PPACK solution and dried . One group was
counted in a well counter : the other was deployed in a shunt
at the site of a thrombus for 15 min and then counted, The
average number of counts on the six balloons that were only
dip coated was 80,552
.
15,686 cpm
. The average number of
Figure 3. Effect of local delivery of PPACK on platelet-dependent
thrombus formation
. A hydrogel-coated coronary angioplasty bal.
loon was inflated at the site of a thrombus and left in place for 15 min
(solid bar). The balloon was removed, and the shunt was recon-
nected to the animal
. There was a significant inhibition of platelet
deposition (p < 0.05) for at least 45 min after the shunt was
eeeonnected(30 to 75 min) .
ax
011
0.0
0
Table 1. Effect of Intravenous Administration of PPACK on Hleeding Time and Activated Partial
Thromboplastin Time
Bleeding time (mm1
	
4
.0 _ 03 4,3'_ 0.1
AM (s)
42 x 4 33 _ 2
There war a significant increase Ip < 0.0011 in both
-,able,
with the I 2 .`-pgk.- per min dose. APIT = activated
partial thromboplasln time .
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PPACK Dose
5.0 vg2og Per non 1 2 .5 ppkg per min
1 .6 :'07 6.500 .3'
76 ' 3 109 3'
counts on the six balloons that were dip coated and deployed
was 39,032
r
7 .873 cpm . The specific activity of the PPACK
solution was 4,087 cpm/µl . Therefore, there was 70 µg of
PACK absorbed onto the balloon whereas 31 .5 Ag re-
mained on the balloons after deployment . The maximal
amount of PPACK that could have been delivered was
13 .5 Mg . When an intravenous injection of PPACK greater
than the amount used locally was administered (70 yogi to a
separate group of animals (n = 6) . there was no change in
either activated partial thromboplastin or bleeding times .
Discussion
These results demonstrate that intravenous administra-
tion of t'P.ACK, a potent synthetic thrombin inhibitor, can
interrupt platelet-dependent thrombus formation on Dacron
vascular gratis in a dose-dependent manner, The arterio-
venous shunt model used for these experiments uses flow
and geometric characteristics similar to those seen in arterial
systems and has been used extensively to evaluate mecha-
nisms of arterial thrombosis (17). Intravenous administration
of PPACK in doses sufficient to maximally inhibit platelet-
dependent thrombosis produced a significant prolongation of
bleeding and activated partial thromboplastin time measure-
ments . These findings confirm similar studies performed
with systemic PPACK therapy in baboons
(6). However,
local administration of PPACK with a hydrogel-coated bal-
loon also inhibited thrombus formation, with no significant
alteration in bleeding variables . The dose of PPACK neces-
sary for inhibirion with local delivery was several orders of
magnitude less than the dose required intravenously . The
inhibition obtained with local delivery persisted for at least
45 min after the balloon was removed .
Mechanism of action of systemic PPACK administration,
The compound PPACK causes potent, irreversible inhibition
of thrombin by reversible active-site complex foration,
followed by rapid, irreversible alkylation of active center
histidine by the chloromethyl ketone (18). The overall rate
constant for these reactions has been reported to be 1
.2 x
10
7 ;mol/liter) -1 -s -1 (19) . When PPACK binds to thrombin,
it forms a PPACK-thrombin complex that binds avidly to
high affinity, functional thrombin receptors on platelets (20) .
This PPACK-thrombin complex prevents the binding of
thrombin at the active site and, as a result, inhibits thrombin-
induced platelet activation (18,20,21)
. In addition, PPACK
1592
NUNES ET AL .
	
JACC V0- 23
. No. 7
LOCAL THROMBOSIS INHIBITION WITH A BALLOON CATHETER lone 1994: 1 578 -n3
may also inactivate platelet membrane-bound meizothrom-
bin during thrombin generation
(22) . The inhibition of plate-
let activation by PPACK is highly specific, as no effects are
seen on platelet aggregation induced by receptor mediated
agonists . such as adenosine diphosphate, collagen, epineph-
rine or ristocelin (6,21).
Another possible mechanism of
action for the inhibition of thrombosis with PPACK admin-
istration seen in these experiments could be the binding of
PPACK to clot-bound thrombin . Previous reports have
shown that thrombin bound to fibrin is enzymatically active
(23,24) and is protected from inhibition by the heparin-
antithrombin III complex (25).
In a recent report, WeitZ et
al. 123) demonstrated that although clot-bound thrombin is
protected from inhibition by heparin-antithrombin III, it may
be readily accessible to iow molecular weight thrombin
inhibitors, such as PPACK
. Presumably, intravenous infu-
sion of PPACK requires that the receptors on circulating
platelets or clot-bound thrombin be saturated by this com-
plex before platelet activation by thrombin is blocked
.
Because bleeding times and activated partial thromboplastin
times are prolonged, intravenous administration of PPACK
probably inactivates thrombin at sites of microvascular
platelet plug formation as well as the thrombin formed during
platelet deposition on the Dacron grafts .
Proposed mechanism of tally delivered PPACK . In the
present study, inflation of a coronary angioplasty balloon at
the site of the forming thrombus for 15 min caused fewer
platelets to be deposited over the first hour of the experiment
for two reasons: l) the physical presence of the balloon
inhibited contact of the thrombus with the bloodstream, and
2) the mechanical action of the balloon could have deformed
the thrombus in a manner that altered the rate of platelet
deposition . The mechanism of inhibition of thrombus forma-
tion by PPACK delivered from the coated balloon is proba-
bly due to the inactivation of clot-bound thrombin because
the dose of PPACK used was inadequate for systemic
anticoagulation, as shown by the absence of a prolongation
of systemic bleeding variables
. The method of delivery of
PPACK also facilitated the inhibition of clot-bound thrombin
because balloon inflation directly at the site of the thrombus
undoubtedly facilitated the delivery of PPACK to thrombin
binding sites on the surface of or within the thrombus
. The
decrease :3 platelet deposition observed after withdrawal of
the balloon probably represented fragmentation of small
amounts of deposited thrombus . The gradual increase in
platelet deposition after the nadir in platelet deposition was
probably due to the exposure of and subsequent platelet
deposition on previously unavailable unoccupied thrombin
binding sites on platelets within the thrombus that were
exposed to circulating blood after partial fragmentation of
the thrombus. The duration of the inhibition of platelet-
dependent thrombosis is consistent with previous observa-
tions and indicates that the inhibitory effect of nonheparin
thrombin inhibitors on clot-bound thrombin can persist for
hours after the thrombin inhibitor is cleared from the circu-
lation (26) . The profound effect of the exceedingly small dose
of PPACK delivered with the coated balloon is probably due
to the fact that the PPACK was delivered directly at the site
of the thrombus .
Comparison of local versus systemic delivery . In a 30-kg
animal, the total dose of the intravenously administered
antithrombin compound necessary for inhibition of throm-
bus formation for a period of 45 min was 16.9 mg. A
significant prolongation of bleeding and activated partial
thromboplastin times was associated with drug administra-
tion
. In contrast, when the hydrogel-coated balloon was
used to deliver the antithrombin compound for a similar
inhibition of thrombosis, the total amount of PPACK neces-
sary was ^-33 pg. In addition, there was no change in
bleeding variables with doses used for kcal delivery
. These
results demonstrate that thrombosis can be inhibited with
local delivery of an agent at a dose < 11500 times the amount
required systemically
. Thus, methods for local delivery of
compounds directly to sites of interest may represent an
important development in the treatment of arterial throm-
botic events . A major challenge will be the successful
application of these techniques and devices to clinical use
.
We thank Gus D. Cipolla, DVM
. and Norman Tanmna, DVM . for their
eacelknl tecbnval assissance .
References
I . Dr. K
. Hdabkov R, Kelsey 5. It al . Peroutaneous uoeslumioal
coronmy, angiophsty in 1915-1956 and i977-1981
. The National Mean .
Lung, and Blood Institute Registry . N Engl J Med 1958318 :285
.70.
2
. Mimno K, Satamurs K, Miyameto A. et al. Angiouopic evduntion of
eoramrywnary thrombi in acute coronary syndromes . N Eogl I Med
1992326 :267-41 .
3. Fuser V . Badman L, Badimon 1L Chesebm JH . The pathogenesis of
coroney mety donate and the acute eneonaty, syndromes (first of two
pans) . N EV J Med t992329:242-50.
4. Fan E . Unsubtle, angina with fatal mtane
: dynamic cmanacy tluombn
In lading to infuctian aod!a sudden death. Circulation 190
.5;11 :a9-
798 .
5 . Cadroy Y . Hmbeu TA. Hanuo SR . Diutiminalins between platekt-
mediated and coagulation-mediated mechanisms in a model of canpks
thrornhus formation m vivo.l LabClin Mod 1959;113:436-48.
6. Hanson SR. Huker LA. lntemrpion oracute pmelet
.dependem thum-
bosis by the synthetic aeoithroalbin D•p henylnBayl-L-pmlyl •L-ntgknyl
chbmmethyl kitten . Floe Nail And Sei VSA 1993.5:3184-8 .
7. Hens M. Chesebro JO, Peony WJ. B iky KR, BoBmon L . Pastes V
.
Edeels of thrmnbin inhibition on the development of acme platelet .
thrombus deposition during angioplauy in pins . Nepatin versus recom6i-
nant bimdis
. a specific lhombin lohibily . Circulation I%9;79 :f37-65.
8. Jackson CM . Nemetson Y. Blood coagulation. Anna Rev Biochem
1900 ;49 :765-511.
9 . Davie EW. Fujikawa K. K.-hi K, Kiniel W
. The Into of sense
pruleases in the blood coagulation cascade . Adv Enaymol 1979;48
:277-
318 .
10. Harker LA. Pathogenesis or thmmbonis
. In
: Williams WJ, Betake
E.
Eater AL LkMman MA . editors. Hematology 4th ed
. New Vork
:
McGraw-Hill. 1990:1559-69.
It . Kelly An, Marue UM
. Kmpski W, et at . Hitudin imetnlption of
tepdn•resistant arterial thrombus formation in baboons
. Blood 1991 ;71:
196-12 .
12. Jung IK, Gold HK, Ziskind AA . Leinbach RC, Potion 1T, Cotton D.
Pnvemion of plaktet-rich
mend
thrombosis by sekaliee thrombin
inhibition. Cisculatitm 19W.11019-25.
JACC Val . 23. No . 7
	
NUNES E'r AL.
June 1VM
:1578-83
LOCAL THROMBOSIS INHIBITION WITH A BALLOON CATHETER
13. Lumsden AB . Kolm HF. Hansson SR
. Hooker LA. Brief topical applica-
n of synthetic amithrmbi, prevents vascular graft thrombosis
. Slog
Forum 1991 ;42 :320-I .
Is
. Committee on Care and Use of Laboratory Animals of the Institute of
Laboratory Animal Resources Commission on Life Sciences. Guide for
the Care and Use of Laboratory Animals. Bethesda (MD)
:
National
Instimres of Health ; Publication No . B5-23: 19841-83.
15. Hanson SR . Rome HF . Savage B . Hacker LA. Pt
.odet intelactiors 01111
Ducron vascular grafts
: a model ofaeute thrombosis in baboons . AOono-
selcensis 1995:5:59.°-fill3
1
6 . Fan YL
. Hydrophilic lubricious coating LIS PeArl 5A9l .2o5 : 19911,
7 . Hacker LA . Kelly AB. Hanson SR
. Eapenmemal onedal thrombosis in
non human pdmmes . Circulation 1991 :83 Suppl IV:10.J1-55
.
18
. Collar D, Matsuo 0, Stassen Jhl . Keurer C, Shaw E . 1 Lab Clin \led
1982 ;99;76-83 .
19 . Keur er C, Shaw E
. e-Phe-Pro-Arg CH2CI . A selector affinity label for
thrombin . Thromb RI, 1979:H:969-73 .
20 . HarmoelT. Jamie", GA
. Activation of plmclcrs by alpha-thrombin is a
receptor-mediated evem . 1 Bier Cheer 1986 :261 :159_28_31.
:583
21 . Greco NJ . Tenor TE
. Tandon NN, Jamieson GA. P?ACK-tiumar in
inhibits thmmbin-induced piaelet aggregation and cytaplasmic acidiPca-
nn bar does not inhibit platelet shape change . Blood 199Q75:1983-9O.
' . Lindhout T. Buruch D. Schoen P. Frenssne J : Hemker HC . Thrombie
generation and inlVdvation in the presence of anlithrombin III and
heparin Biochemistry I9B625 :5962-9.
t. Weita JL Hoboda St . Maszel D. Margganorc 1, Hirsh 1. Clot-board
rhmmtln is protected from inhibition by hepannanliihrombin III but is
-cepible to inactivation by antirhrmbin III-independent inhibitors .
J Can Im'29
1990:86:385-91.
V
. Van Z. Scheraga HA . Localisation of the binding site on fibrin for the
secondary binding site affirmative . Biochemistry 1983;27
:1956-63 .
25 . Hogg TI.1zckson CM. Fibrin monomer prefects thrombin from inactiva-
Iron by heparin-anlithrombin III
: implications for heparin efcacy . Proc
Null Acad Set USA 1989;86'3619 _3 .
26 . Agrcll, C . Senga C
. Weitz 3: . Nenci DO . Honk I . Sustaired antithrom-
bod St Audio after rn plasma clearance c eon with
heparin 31 aaJ 1992M :%0-1.
